atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Alzheimer’s disease is the most common cause of dementia, responsible for up to 80% of dementia cases worldwide.
In a mouse model, KCL-286, a drug that has passed phase 1 trials for spinal injuries in people, repaired DNA breaks and…
Neko Health has raised US$700m to fund its first US expansion, new clinics and further development of its preventative health tech.
The Series C round follows a US$260m Series B in January 2025.
Founded by Spotify’s Daniel Ek and Hjalmar…
Attendees
Sponsors and Exhibitors
Contact us